TRAWS PHARMA INC (TRAW) Stock News

USA - NASDAQ:TRAW - US68232V8845 - Common Stock

2.98 USD

-0.09 (-2.93%)

Last: 10/21/2025, 7:17:50 PM

2.95 USD

-0.03 (-1.01%)

After Hours: 10/21/2025, 7:17:50 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TRAW Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Traws Pharma, Inc.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

8 days ago - By: Traws Pharma, Inc.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

16 days ago - By: Traws Pharma, Inc.

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

16 days ago - By: Traws Pharma, Inc.

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

2 months ago - By: The Motley Fool - Mentions: ONTX

Traws Pharma Posts Q2 Revenue Jump

a month ago - By: Annovis Bio Inc. - Mentions: ANVS

Annovis Appoints Mark Guerin as Chief Financial Officer

a month ago - By: Benzinga - Mentions: APRE CODX RNAZ ISPC ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

2 months ago - By: Benzinga - Mentions: NBY PHR IMCC PMN ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: Traws Pharma, Inc.

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

2 months ago - By: Traws Pharma, Inc.

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

2 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

2 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

2 months ago - By: Traws Pharma, Inc.

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

2 months ago - By: Traws Pharma, Inc.

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

4 months ago - By: Stocktwits - Mentions: MRNA NVAX CVAC GSK

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

4 months ago - By: Traws Pharma, Inc.

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

4 months ago - By: Traws Pharma, Inc.

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

5 months ago - By: Traws Pharma, Inc.

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

5 months ago - By: Traws Pharma, Inc.

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

5 months ago - By: Traws Pharma, Inc.

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

5 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

5 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

7 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports Full Year 2024 Results and Business Highlights

7 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports Full Year 2024 Results and Business Highlights

7 months ago - By: Traws Pharma, Inc.

Traws Pharma Announces Management Updates

7 months ago - By: Traws Pharma, Inc. - Mentions: IOVA IKNA

Traws Pharma Announces Management Updates

7 months ago - By: Traws Pharma, Inc.

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

7 months ago - By: Traws Pharma, Inc.

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET